SCHEDULE 13G/A: OBF Investments and George H. Scholl Disclose 4.4% Stake in iSpecimen Inc. Following Reverse Stock Split

OBF Investments, LLC and George H. Scholl have reported beneficial ownership of 4.4% of iSpecimen Inc.'s common stock, reflecting holdings after the company's one-for-twenty reverse stock split.

Summary

• OBF Investments, LLC and George H. Scholl have filed an Amendment No. 3 to Schedule 13G, disclosing their beneficial ownership in iSpecimen Inc.
• OBF Investments, LLC beneficially owns 42,100 shares of iSpecimen Inc. common stock, representing 4.4% of the class.
• George H. Scholl beneficially owns 42,263 shares of iSpecimen Inc. common stock, also representing 4.4% of the class.
• Mr. Scholl's reported ownership includes the 42,100 shares held by OBF Investments, LLC, where he serves as President and Chief Executive Officer.
• Additionally, Mr. Scholl's holdings include 163 shares issued from the vesting and settlement of restricted stock units (RSUs) received as compensation for his service as a director of iSpecimen Inc.
• All reported share amounts reflect the one-for-twenty reverse stock split implemented by iSpecimen Inc. on September 13, 2024.
• The percentage of class is calculated based on 962,637 shares of common stock outstanding as of November 4, 2024, as reported in iSpecimen Inc.'s Quarterly Report on Form 10-Q filed on November 7, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative operational or financial news.

Positives

• The filing provides transparency regarding significant beneficial ownership stakes in iSpecimen Inc.
• Disclosure of a vested interest by an investment entity and an individual, indicating alignment with shareholder interests.

Future Outlook

NA

Management Comments

• "All share amounts reflect the one-for-twenty reverse stock split effected by the Issuer on September 13, 2024."
• "Percent of class is calculated based on 962,637 shares of common stock outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission on November 7, 2024."
• "As the President and Chief Executive Officer of OBF Investments, LLC, Mr. Scholl may be deemed to beneficially own the 42,100 shares of common stock held by OBF Investments, LLC."
• "Share amounts also include a total of 163 shares of common stock issued upon the vesting and settlement of restricted stock units ('RSUs') previously awarded to Mr. Scholl as compensation for his service as a director of the Issuer."

Industry Context

This filing is a routine disclosure of beneficial ownership and does not provide specific industry context or trends. It indicates a significant, but non-controlling, stake held by an investment entity and an individual in the biotechnology or healthcare services sector, where iSpecimen Inc. operates.

Comparison to Industry Standards

• NA. This document is a regulatory filing detailing specific ownership percentages and does not provide data for comparison to industry benchmarks or competitor performance.

Corporate Governance

Related Party Transactions

• George H. Scholl, as a director of iSpecimen Inc., received 163 shares of common stock from the vesting and settlement of restricted stock units (RSUs) as compensation for his service. This is a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: Provides transparency regarding significant beneficial ownership stakes, which can influence perceptions of company control and stability.
• Investors: Offers insight into the holdings of key individuals and investment entities, which may be considered in investment decisions.

Key Dates

Keywords

iSpecimen Inc., OBF Investments LLC, George H. Scholl, Schedule 13G, Beneficial Ownership, Common Stock, Reverse Stock Split, SEC Filing, Shareholder Disclosure, Investment